Tempest Therapeutics, Inc. (TPST)
Largest Insider Buys in Sector
TPST Stock Price History Chart
TPST Stock Performance
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was …
Insider Activity of Tempest Therapeutics, Inc.
Over the last 12 months, insiders at Tempest Therapeutics, Inc. have bought $100,001 and sold $967,033 worth of Tempest Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Tempest Therapeutics, Inc. have bought $2.56M and sold $967,033 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Brady Stephen R (President and CEO) — $73,850. Trojanowski Justin (Corporate Controller) — $16,200. Whiting Samuel (Chief Medical Officer) — $9,951.
The last purchase of 35,000 shares for transaction amount of $73,850 was made by Brady Stephen R (President and CEO) on 2024‑07‑03.
List of Insider Buy and Sell Transactions, Tempest Therapeutics, Inc.
| 2024-08-12 | Sale | 10 percent owner | 387,999 2.043% | $1.10 | $426,993 | +39.50% | ||
| 2024-08-08 | Sale | 10 percent owner | 400,000 1.814% | $1.35 | $540,040 | -0.75% | ||
| 2024-07-03 | President and CEO | 35,000 0.1539% | $2.11 | $73,850 | 0.00% | |||
| 2024-07-02 | Chief Medical Officer | 4,672 0.0207% | $2.13 | $9,951 | 0.00% | |||
| 2024-06-28 | Corporate Controller | 7,500 0.0338% | $2.16 | $16,200 | 0.00% | |||
| 2022-04-29 | 2.12M 11.9674% | $2.36 | $5M | -44.60% | ||||
| 2022-01-07 | President | 2,000 0.0288% | $4.78 | $9,560 | -47.68% | |||
| 2022-01-06 | Chief Medical Officer | 1,700 0.0243% | $4.80 | $8,168 | -48.40% | |||
| 2016-06-01 | Chief Executive Officer | 425,000 1.3568% | $7.00 | $2.98M | -53.63% | |||
| 2016-06-01 | director | 425,000 1.3568% | $7.00 | $2.98M | -53.63% | |||
| 2016-05-18 | Chief Executive Officer | 20,000 0.0671% | $7.86 | $157,200 | -53.14% | |||
| 2016-05-18 | director | 20,000 0.0671% | $7.86 | $157,200 | -53.14% | |||
| 2016-05-17 | Chief Executive Officer | 20,000 0.0677% | $7.56 | $151,200 | -50.67% | |||
| 2016-05-17 | director | 20,000 0.0677% | $7.56 | $151,200 | -50.67% | |||
| 2016-05-16 | Chief Executive Officer | 20,000 0.0668% | $7.69 | $153,800 | -51.69% | |||
| 2016-05-13 | Chief Executive Officer | 16,295 0.055% | $7.06 | $115,043 | -46.48% | |||
| 2016-05-13 | director | 16,295 0.055% | $7.06 | $115,043 | -46.48% | |||
| 2016-05-12 | Chief Executive Officer | 19,800 0.0679% | $6.84 | $135,352 | -43.52% | |||
| 2016-05-12 | director | 19,800 0.0679% | $6.84 | $135,352 | -43.52% | |||
| 2016-05-11 | Chief Executive Officer | 20,000 0.0709% | $7.64 | $152,800 | -47.08% |
Insider Historical Profitability
| Brady Stephen R | President and CEO | 46376 0.1746% | $1.01 | 1 | 0 | |
| Trojanowski Justin | Corporate Controller | 22168 0.0834% | $1.01 | 1 | 0 | |
| Whiting Samuel | Chief Medical Officer | 9573 0.036% | $1.01 | 2 | 0 | <0.0001% |
| Westphal Christoph H | 3820571 14.3815% | $1.01 | 2 | 0 | ||
| Longwood Fund, L.P. | 10 percent owner | 3820571 14.3815% | $1.01 | 2 | 0 |
Institutional Investor Ownership
| BlackRock | $1.99M | 2.29 | 508,195 | -0.14% | -$2,866.03 | <0.0001 | |
| Fidelity Investments | $1.69M | 1.94 | 431,982 | +0.01% | +$195.50 | <0.0001 | |
| The Vanguard Group | $688,914.00 | 0.79 | 176,193 | 0% | +$0 | <0.0001 | |
| Geode Capital Management | $516,519.00 | 0.6 | 132,083 | +4.9% | +$24,108.63 | <0.0001 | |
| Fil Ltd | $506,654.00 | 0.58 | 129,579 | 0% | +$0 | <0.0001 |